Biosynthesis and biotechnological production of statins by filamentous fungi and application of these cholesterol-lowering drugs

Applied Microbiology and Biotechnology

Volumn 58, Issue 5, 2002, Pages 555-564

  Manzoni, Matilde ^a   Rollini, M ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ATORVASTATIN; BMS 188494; CERIVASTATIN; COMPACTIN; ENZYME INHIBITOR; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN; MEVINOLIN; MONACOLIN J; MONACOLIN L; MONACOLIN M; MONACOLIN X; NAPHTHALENE DERIVATIVE; POLYKETIDE; PRAVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

BIOTECHNOLOGY;

ASPERGILLUS TERREUS; BIOSYNTHESIS; BIOTECHNOLOGICAL PROCEDURES; CARDIOVASCULAR RISK; CHEMICAL MODIFICATION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CORONARY ARTERY DISEASE; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSFORMATION; ENZYME INHIBITION; ENZYME SUBSTRATE; FUNGUS; HUMAN; HYPERCHOLESTEROLEMIA; METABOLITE; NONHUMAN; PENICILLIUM CITRINUM; PREDICTION; RISK BENEFIT ANALYSIS; SHORT SURVEY; STREPTOMYCES; STREPTOMYCES CARBOPHILUS;

BIOTECHNOLOGY; FUNGI; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MODELS, CHEMICAL;

ASPERGILLUS; ASPERGILLUS TERREUS; FUNGI; PENICILLIUM; PENICILLIUM CITRINUM; STREPTOMYCES; STREPTOMYCES CARBOPHILUS;

EID: 0036222207     PISSN: 01757598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00253-002-0932-9     Document Type: Short Survey

References (91)

1. Discovery, biochemistry and biology of lovastatin
2. Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and cholesterol-lowering agent
3. Pravastatin sodium (CS-514), a novel cholesterol-lowering agent which inhibits HMG-CoA reductase
4. Lovastatin nonaketide synthase catalyzes an intramolecular Diels-Alder reaction of a substrate analogue
5. Conversion of cyclic nonaketides to lovastatin and compactin by a lovC deficient mutant of Aspergillus terreus
6. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia
7. Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase
8. Novel approaches to lipid lowering: What is on the horizon?
9. Production of lovastatin, an inhibitor of cholesterol accumulation in humans
10. Biosynthesis of mevinolin. Spectral assignment by double-quantum coherence NMR after high carbon-13 incorporation
11. Clinically relevant differences between the statins: Implications for therapeutic selection
12. Pharmaceutically active secondary metabolites of microrganisms
13. Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients
14. Cholesterol lowering in the management of coronary artery disease: The clinical implications of recent trials
15. Monacolin K, a new hypocholesterolemic agent produced by Monascus species
16. Monacolin K, a new hypocholesterolemic agent that specifically inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase
17. Compactin (ML236B) and related compounds as potential cholesterol-lowering agents that inhibit HMG-CoA reductase
18. Microbial phosphorylation of compactin (ML-236B) and related compounds
19. Dihydromonacolin L and Monacolin X, new metabolites those inhibit cholesterol biosynthesis
20. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites having hypocholester-olemic activity
21. ML-236A, ML-236B and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum
22. Monacolins J and L, new inhibitors of cholesterol biosynthesis produced by Monascus ruber
23. Biosynthesis of ML-236B (compactin) and monacolin K
24. Monacolin M, a new inhibitor of cholesterol biosynthesis
25. The synthesis of compactin (ML-236B) and monacolin K in fungi
26. Current and future treatment of hyperlipidemia: The role of statins
27. Statins as cellular antithrombotics
28. Natural statins and stroke risk
29. Effect of HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia
30. Mevinolinic acid biosynthesis byAspergillus terreus and its relationship to fatty acid biosynthesis
31. Screening fungi for the production of an inhibitor of HMG-CoA reductase: Production of mevinolin by the fungi of the genus Pleurotus
32. Structure elucidation of the bioactive metabolites of ML-236B (mevastatin) isolated from dog urine
33. Lovastatin biosynthesis in Aspergillus terreus: Characterization of blocked mutants, enzyme activities and multifunctional polyketide synthase gene
34. Chiral total synthesis of compactin
35. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side chain ester derivatives of mevinolin
36. Different metabolism of statins: Importance in drug-drug interactions
37. Morphology study in production of ML-236B, a precursor of pravastatin sodium, by Penicillium citrinum
38. Morphology control of preculture during production of ML-236B, a precursor of pravastatin sodium, by Penicillium citrinum
39. Fuzzy control in microbial production of ML-236B, a precursor of pravastatin sodium
40. Application of computer to monitoring and control of fermentation process: Microbial conversion of ML-236B to pravastatin
41. Total synthesis of the hypocholesterolemic agent compactin
42. Aspects of the biosynthesis of non-aromatic fungal polyketides by iterative polyketide synthases
43. The structure of the catalytic portion of human HMG-CoA reductase
44. Structural mechanism for statin inhibition of HMG-CoA reductase
45. Crystal structure of the catalytic portion of human HMG-CoA re-ductase: Insights into regulation of activity and catalysis
46. Secondary metabolites of the fungusMonascus: A review
47. Modulation of polyketide synthase activity by accessory proteins during lovastatin biosynthesis
48. Biosynthesis of monacolins: Conversion of monacolin J to monacolin K (mevinolin)
49. Cataracts produced by triparanol (MER-29)
50. Biosynthesis of monacolins: Conversion of monacolin L to monacolin J by a monooxygenase of Monascus ruber
51. From phenotypes to genotypes: A remarkable quarter century. A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin
52. Production and purification of statins from Aspergillus terreusstrains
53. Production of statins by filamentous fungi
54. Current perspective on statins
55. sca in Streptomyces carbophilus that hydroxylates ML-236B to pravastatin sodium (CS-514), a tissue-selective inhibitor of 3-hydroxy-3-methylglutaril coen-zyme A reductase
56. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitor
57. HMG-CoA reductase inhibitors, and the risk of fracture
58. 13C NMR and mass spectrometry
59. Productivity of monacolin K (mevinolin) in the genus Monascus
60. Statin therapy and reductions in low-density lipoprotein cholesterol. Initial clinical data on the potent new statin rosuvastatin
61. Synthesis of chiral drug intermediates
62. A new hydrolase system in Actinomadura sp cells converting compactin to pravastatin
63. Biotransformation of compactin to pravastatin by Actinomadura sp. 2966
64. Antiatherothrombotic proportion of statins: Implications for cardiovascular event reduction
65. Microbial hydroxylation of ML236B (compactin) and monacolin K (MB-530B)
66. 3α-hydroxy-ML-236B (3α-hydroxycompactin), microbial transformation product of ML-236B (compactin)
67. Microbial hydroxylation of ML-236B (compactin) studies on microrganisms capable of 3β-hydroxylation of ML-236B
68. Biochemical and fermentation technological approaches to production of pravastatin, a HMG-CoA reductase inhibitor
69. Biosynthesis of mevinolin, a hypocholes-terolemic fungal metabolite, in Aspergillus terreus
70. Comparison of statins in hypertriglyceridemia
71. Effect of triparanol (MER-29) on cholesterol biosynthesis and on blood sterol levels in man
72. Recent advances in the biosynthetic studies of lovastatin
73. Randomized trial of cholesterol lowering in 4444 patients with coronary hearth disease: The Scandinavian Survival Study (4 S)
74. New developments in lipid-lowering therapy: The role of inhibitors of hydroxymethylglutaryl coenzyme A reductase
75. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutar-yl coenzyme A reductase: Tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species
76. The evolving role of statins in the management of atherosclerosis
77. New micro-organisms which convert compactin to pravastatin